ctdna and hrd analysis of a phase ii trial of atezolizumab combo in recurrent ovarian cancer
Published 3 months ago • 39 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
0:58
real-world monitoring of circulating tumor dna to predict cancer recurrence
-
4:26
fundamentals of ctdna
-
1:21
evaluating the interchangeability of hrd testing in ovarian cancer
-
0:33
why ovarian cancer drugs stop working?
-
50:02
recurrent ovarian cancer (2022)
-
12:01
debate: is circulating tumor dna ready to guide adjuvant therapy in colon cancer? - yes
-
0:45
the emerging role of ctdna in cancer diagnostics
-
0:53
"how can ctdna improve detection and monitoring of my specific cancer?”
-
29:07
actg dinner symposium highlights | beyond brca testing – does hrd matter? | prof michael friedlander
-
2:26
dr. goetz on the use of ctdna in the monarch-3 trial in hr /her2- breast cancer
-
3:44
ctdna as a diagnostic, prognostic, and predictive biomarker for lung cancer
-
1:36
rechallenge with egfr inhibitors in ctdna ras/braf wt refractory mcrc
-
5:10
circulating tumor dna (ctdna) to reshape clinical trial design in early stage cancers
-
0:51
what the future may hold for ctdna in cancer screening and diagnosis
-
3:07
future uses of ctdna measurements: changing the treatment landscape
-
1:37
the role of ctdna in hodgkin lymphoma
-
3:25
understand ctdna testing
-
2:16
dr. dottino on molecular detection of recurrent ovarian cancer
-
1:25
moffitt medical minute - circulating tumor dna (ep. 9)